Efficacy & Safety in Moderately Active Refractory Ulcerative Colitis Patients
Status:
Terminated
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
This study is designed as a proof of concept of KRP203 for induction of remission in
ulcerative colitis (UC). The purpose of this study is to evaluate clinical benefit of KRP203
in subjects with moderately active refractory ulcerative colitis.
The study will provide safety and tolerability data in this subject population up to eight
weeks of treatment with KRP203. Additionally, this study will evaluate the duration of a
clinical response to KRP203 by following up responding subjects for an additional 12 weeks.